Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.

Source Fool.com

Resmed Inc. Aktie

Mittlere Gewinne bei Resmed Inc. heute, der Kurs steigt um 1,20 %.
Eine klare Tendenz zu Buy-Einschätzungen bei Resmed Inc., ohne Sell-Einschätzungen.
Ein Kursziel von 256 € für Resmed Inc. könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 202.8 € führen.

Like: 0

RMD

Teilen